A pH-Responsive Zwitterionic Polyurethane Prodrug as Drug Delivery System for Enhanced Cancer Therapy.
Adriamycin
antitumor
pH-responsive polyurethane
zwitterionic
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
31 Aug 2021
31 Aug 2021
Historique:
received:
30
07
2021
revised:
14
08
2021
accepted:
19
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Numerous nanocarriers with excellent biocompatibilities have been used to improve cancer therapy. However, nonspecific protein adsorption of nanocarriers may block the modified nanoparticles in tumor cells, which would lead to inefficient cellular internalization. To address this issue, pH-responsive polyurethane prodrug micelles with a zwitterionic segment were designed and prepared. The micelle consisted of a zwitterionic segment as the hydrophilic shell and the drug Adriamycin (DOX) as the hydrophobic inner core. As a pH-responsive antitumor drug delivery system, the prodrug micelles showed high stability in a physiological environment and continuously released the drug under acidic conditions. In addition, the pure polyurethane carrier was demonstrated to be virtually non-cytotoxic by cytotoxicity studies, while the prodrug micelles were more efficient in killing tumor cells compared to PEG-PLGA@DOX. Furthermore, the DOX cellular uptake efficiency of prodrug micelles was proved to be obviously higher than the control group by both flow cytometry and fluorescence microscopy. This is mainly due to the modification of a zwitterionic segment with PU. The simple design of zwitterionic prodrug micelles provides a new strategy for designing novel antitumor drug delivery systems with enhanced cellular uptake rates.
Identifiants
pubmed: 34500707
pii: molecules26175274
doi: 10.3390/molecules26175274
pmc: PMC8434572
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Drug Carriers
0
Micelles
0
Polymers
0
Polyurethanes
0
Prodrugs
0
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Macromol Rapid Commun. 2012 Jun 14;33(11):1003-7
pubmed: 22323316
Biomacromolecules. 2016 Jun 13;17(6):2010-8
pubmed: 27050797
Molecules. 2021 May 04;26(9):
pubmed: 34064416
J Mater Chem B. 2016 Aug 21;4(31):5256-5264
pubmed: 32263606
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Colloids Surf B Biointerfaces. 2014 Apr 1;116:424-31
pubmed: 24549044
Langmuir. 2020 Mar 10;36(9):2383-2395
pubmed: 32036662
Adv Mater. 2015 Jan 7;27(1):15-26
pubmed: 25367090
Colloids Surf B Biointerfaces. 2014 Mar 1;115:384-90
pubmed: 24503292
Medchemcomm. 2016 Dec 21;8(2):415-421
pubmed: 30108759
Int J Pharm. 2021 May 1;600:120502
pubmed: 33746010
Int J Pharm. 2020 Apr 30;580:119231
pubmed: 32194207
Molecules. 2021 Apr 19;26(8):
pubmed: 33921892
Biomaterials. 2013 Jun;34(19):4680-9
pubmed: 23537665
Mater Sci Eng C Mater Biol Appl. 2016 Mar;60:569-578
pubmed: 26706565
Molecules. 2021 Jun 10;26(12):
pubmed: 34200947
Langmuir. 2021 May 18;37(19):5776-5782
pubmed: 33966385
Chem Soc Rev. 2019 Oct 28;48(21):5381-5407
pubmed: 31495856
Langmuir. 2019 Feb 5;35(5):1273-1283
pubmed: 29933695
Chem Rev. 2015 Aug 26;115(16):8564-608
pubmed: 26259712
J Colloid Interface Sci. 2017 Jan 1;485:251-259
pubmed: 27676086
Angew Chem Int Ed Engl. 2014 Feb 10;53(7):1746-54
pubmed: 24446141